@article {10440,
	title = {Neuronal Dysfunction Associated with Cholesterol Deregulation.},
	journal = {Int J Mol Sci},
	volume = {19},
	year = {2018},
	month = {2018 May 19},
	abstract = {<p>Cholesterol metabolism is crucial for cells and, in particular, its biosynthesis in the central nervous system occurs in situ, and its deregulation involves morphological changes that cause functional variations and trigger programmed cell death. The pathogenesis of rare diseases, such as Mevalonate Kinase Deficiency or Smith$^{-}$Lemli$^{-}$Opitz Syndrome, arises due to enzymatic defects in the cholesterol metabolic pathways, resulting in a shortage of downstream products. The most severe clinical manifestations of these diseases appear as neurological defects. Expanding the knowledge of this biological mechanism will be useful for identifying potential targets and preventing neuronal damage. Several studies have demonstrated that deregulation of the cholesterol pathway induces mitochondrial dysfunction as the result of respiratory chain damage. We set out to determine whether mitochondrial damage may be prevented by using protective mitochondria-targeted compounds, such as MitoQ, in a neuronal cell line treated with a statin to induce a biochemical block of the cholesterol pathway. Evidence from the literature suggests that mitochondria play a crucial role in the apoptotic mechanism secondary to blocking the cholesterol pathway. Our study shows that MitoQ, administered as a preventive agent, could counteract the cell damage induced by statins in the early stages, but its protective role fades over time.</p>},
	keywords = {Anticholesteremic Agents, Cell Line, Tumor, Cholesterol, Electron Transport, Humans, Lovastatin, Mitochondria, Neurons, Neuroprotective Agents, Organophosphorus Compounds, Ubiquinone},
	issn = {1422-0067},
	doi = {10.3390/ijms19051523},
	author = {Marcuzzi, Annalisa and Loganes, Claudia and Valencic, Erica and Piscianz, Elisa and Monasta, Lorenzo and Bilel, Sabrine and Bortul, Roberta and Celeghini, Claudio and Zweyer, Marina and Tommasini, Alberto}
}
@article {3487,
	title = {NF-κB pathways in hematological malignancies.},
	journal = {Cell Mol Life Sci},
	volume = {71},
	year = {2014},
	month = {2014 Jun},
	pages = {2083-102},
	abstract = {<p>The nuclear factor κB or NF-κB transcription factor family plays a key role in several cellular functions, i.e. inflammation, apoptosis, cell survival, proliferation, angiogenesis, and innate and acquired immunity. The constitutive activation of NF-κB is typical of most malignancies and plays a major role in tumorigenesis. In this review, we describe NF-κB and its two pathways: the canonical pathway (RelA/p50) and the non-canonical pathway (RelB/p50 or RelB/p52). We then consider the role of the NF-κB subunits in the development and functional activity of B cells, T cells, macrophages and dendritic cells, which are the targets of hematological malignancies. The relevance of the two pathways is described in normal B and T cells and in hematological malignancies, acute and chronic leukemias (ALL, AML, CLL, CML), B lymphomas (DLBCLs, Hodgkin{\textquoteright}s lymphoma), T lymphomas (ATLL, ALCL) and multiple myeloma. We describe the interaction of NF-κB with the apoptotic pathways induced by TRAIL and the transcription factor p53. Finally, we discuss therapeutic anti-tumoral approaches as mono-therapies or combination therapies aimed to block NF-κB activity and to induce apoptosis (PARAs and Nutlin-3).</p>},
	keywords = {Antineoplastic Agents, B-Lymphocytes, Carcinogenesis, Dendritic Cells, Gene Expression Regulation, Neoplastic, Hematologic Neoplasms, Humans, Imidazoles, Macrophages, NF-kappa B, Piperazines, Signal Transduction, T-Lymphocytes, TNF-Related Apoptosis-Inducing Ligand, Transcription Factor RelA, Transcription Factor RelB, Tumor Suppressor Protein p53},
	issn = {1420-9071},
	doi = {10.1007/s00018-013-1545-4},
	author = {Gasparini, Chiara and Celeghini, Claudio and Monasta, Lorenzo and Zauli, Giorgio}
}
